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Summary
Background Inappropriate antibiotic prescribing contributes to the generation of drug resistance worldwide, and is 
particularly common in China. We assessed the effectiveness of an antimicrobial stewardship programme aiming to 
reduce inappropriate antibiotic prescribing in paediatric outpatients by targeting providers and caregivers in primary 
care hospitals in rural China.
Methods We did a pragmatic, cluster-randomised controlled trial with a 6-month intervention period. Clusters were 
primary care township hospitals in two counties of Guangxi province in China, which were randomly allocated to the 
intervention group or the control group (in a 1:1 ratio in Rong county and in a 5:6 ratio in Liujiang county). 
Randomisation was stratified by county. Eligible participants were children aged 2–14 years who attended a township 
hospital as an outpatient and were given a prescription following a primary diagnosis of an upper respiratory tract 
infection. The intervention included clinician guidelines and training on appropriate prescribing, monthly prescribing 
peer-review meetings, and brief caregiver education. In hospitals allocated to the control group, usual care was 
provided, with antibiotics prescribed at the individual clinician’s discretion. Patients were masked to their allocated 
treatment group but doctors were not. The primary outcome was the antibiotic prescription rate in children attending 
the hospitals, defined as the cluster-level proportion of prescriptions for upper respiratory tract infections in 
2–14-year-old outpatients, issued during the final 3 months of the 6-month intervention period (endline), that included 
one or more antibiotics. The outcome was based on prescription records and analysed by modified intention-to-treat. 
This study is registered with the ISRCTN registry, number ISRCTN14340536.
Findings We recruited all 25 eligible township hospitals in the two counties (14 hospitals in Rong county and 11 in 
Liujiang county), and randomly allocated 12 to the intervention group and 13 to the control group. We implemented 
the intervention in three internal pilot clusters between July 1, 2015, and Dec 31, 2015, and in the remaining nine 
intervention clusters between Oct 1, 2016 and March 31, 2016. Between baseline (the 3 months before implementation 
of the intervention) and endline (the final 3 months of the 6-month intervention period) the antibiotic prescription 
rate at the individual level decreased from 82% (1936/2349) to 40% (943/2351) in the intervention group, and from 
75% (1922/2548) to 70% (1782/2552) in the control group. After adjusting for the baseline antibiotic prescription rate, 
stratum (county), and potentially confounding patient and prescribing doctor covariates, this endline difference 
between the groups represented an intervention effect (absolute risk reduction in antibiotic prescribing) of –29% 
(95% CI –42 to –16; p=0·0002).
Interpretation In China’s primary care setting, pragmatic interventions on antimicrobial stewardship targeting 
providers and caregivers substantially reduced prescribing of antibiotics for childhood upper respiratory tract 
infections.
Funding Department of International Development (UKAID) through Communicable Diseases Health Service Delivery.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Antimicrobial resistance is universally recognised as a 
threat to global public health.1 A major driver of 
antimicrobial resistance has been a huge increase in 
antibiotic prescribing, especially in low-income and 
middle-income countries (LMICs).2 The greatest source of 
antibiotic prescribing is for upper respiratory tract 
infections in children, which are the most common 
reasons for children to attend primary care facilities.1 
Generally, most upper respiratory tract infections in 
children are viral diseases such as sore throats, for which 
antibiotics are unnecessary. However, antibiotic overuse 
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can lead to the selection of resistant organisms,3 
consequently causing clinical failure when common 
antibiotics are used.1 Several factors affect the use of 
antibiotics, including clinicians’ prescribing behaviours 
and patients’ or caregivers’ knowledge, attitudes, and 
demand for antibiotics. Doctors might also be influenced 
by concerns about missing additional underlying bacterial 
infections, or that viral infections could become 
secondarily bacterially infected.4,5 Behaviour change 
interventions, mainly in high-income countries, have 
shown that educational guidelines and printed educational 
materials for providers have positive but modest 
improvements on prescribing behaviour.6 Recent 
systematic review evidence on antibiotic use for upper 
respiratory tract infections in children shows that 
strategies targeting both providers and caregivers are 
more effective than are those targeting providers alone, 
but no evidence exists for the effectiveness of such 
interventional programmes in LMICs.7
In China, around 70% of outpatients attending primary 
care facilities with colds are inappropriately treated with 
antibiotics, often by intravenous infusion.8 The situation 
is worse in children than in adults because parents or 
caregivers often demand antibiotics.4 In 2012, the Chinese 
Ministry of Health issued a regulation to limit antibiotic 
prescribing to 20% of outpatient prescriptions in all 
patients.9 However, the policy has not been successful, 
with outpatient antibiotic prescribing rates as high as 
80% in recent years.10,11 Following a request by the Chinese 
national health authorities, we developed a comprehensive 
package, targeting both doctors and caregivers, to reduce 
inappropriate pre scribing of antibiotics for upper 
respiratory tract in fections in children within township 
hospitals—the rural primary care facilities—in China.12 
We then tested its effectiveness in a cluster-randomised 
controlled trial, which we report here.
Methods
Study design and setting
We did a pragmatic, parallel-group, cluster-randomised 
controlled trial, stratified by county, comparing our 
intervention with usual care in 25 township hospitals 
within the rural, low-income province of Guangxi in 
western China. China’s rural primary care system contains 
township hospitals and village clinics; the township 
hospitals provide the majority of acute consultations in our 
Research in context
Evidence before this study
Before we began this study, we did a systematic review of 
interventions to reduce antibiotic prescribing for respiratory 
infections in primary care settings. We searched PubMed, 
Cochrane, Embase, and Google Scholar from Jan 1, 1980, to 
Dec 31, 2016, for published studies, using the following 
keywords: “antibiotics”, “antibiotic prescribing”, “primary 
care”, “respiratory infections”, “respiratory diseases”, 
“education”, “training”, “RCT”, and “randomised controlled 
trial”. We identified 129 studies, including 13 trials reporting 
results relating to interventions for reducing antibiotic 
prescription rates in primary care settings. Of these trials, 
11 were done in high-income countries (five in the USA, four 
in Europe, one in Canada, and one in Israel), and two in 
low-income or middle-income countries (LMICs; one in China 
and one in Iran). The duration of interventions ranged from 
3 months to 3 years, targeting either clinicians (nine trials), 
patients or caregivers (one), or both (three). The pooled 
absolute risk reduction in the antibiotic prescription rate for 
intervention versus control was –4·6% (95% CI –6·4 to –2·9; 
p<0·0001). Existing evidence suggested that training using 
guidelines produces a small reduction in the antibiotic 
prescription rate (ie, <5% absolute risk reduction in rate), 
whereas monitoring and feedback of prescribing behaviour 
achieves a slightly higher reduction (7–9%). One study in 
Quebec, Canada, involved patients in decision-making and 
reduced the absolute risk reduction in antibiotic prescription 
rate by 19·8%, but the sample size was small (n=9). 
The two trials in developing countries were not adequately 
designed or reported. Whether or not such interventions 
could be implemented in developing countries where overuse 
of antibiotics is more challenging was unclear.
Added value of this study
To our knowledge, our study was the first cluster-randomised 
trial to be done in a rural primary care setting aiming to 
reduce antibiotic use in LMICs with a relatively large sample 
size. Our intervention included the use of an evidence-based 
prescribing guideline, training and monthly prescribing 
peer-review meetings for doctors, and brief education for 
caregivers during consultations and an educational waiting 
room video for caregivers, and reduced the prescribing of 
antibiotics by 29 percentage points for childhood upper 
respiratory infections in rural Chinese primary care facilities. 
This effect size was much higher than those reported in 
previous studies. Our interventions were designed to be 
embedded within routine primary care, can be integrated into 
China’s rural health-care system, and are ready to be 
scaled-up in China and other developing countries.
Implications of all the available evidence
Antimicrobial stewardship in developing countries should 
consider multicomponent interventions that provide clinical 
guidelines, improve knowledge, implement regular 
peer-review meetings, and provide concise education to 
caregivers and patients. These interventions should be 
designed to fit into routine primary care practice and policy 
settings to ensure effectiveness, sustainability, and scalability. 
Longer-term studies are needed to determine whether or not 
the effect size will be sustained over a long timeframe.
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setting.10,13 The study area covered 1 372 000 rural residents, 
with a median annual income per person of US$1500 in 
2013. Each township hospital provides outpatient care and 
a limited amount of inpatient care to a rural population of 
100 000–200 000 people in its catchment area. We used a 
cluster design because some parts of the intervention (eg, 
peer review meetings) made it infeasible to allocate doctors 
within the same hospital to different groups for logistical 
reasons and because of the risk of contamination. We used 
an internal pilot approach, initially running the trial in 
three intervention clusters and three control clusters, 
before expanding it to all remaining clusters after 
confirming that the trial processes were feasible and 
acceptable (>50% of clinicians trained and using the 
guidelines by 3 months). No changes were made to study 
implementation processes between the pilot and main 
stages, other than some editing of the educational 
materials for ease of understanding. Township hospitals 
were located in Rong county (14 hospitals) and Liujiang 
county (11 hospitals). All township hospitals across the 
two counties were considered eligible, apart from the two 
situated in each county centre because their better staff 
capacity, equipment, and close proximity to the county 
general hospital made their practice quite different from 
that in the other township hospitals. Before randomisation, 
the trial manager sought written informed consent from 
township hospital directors on behalf of the township 
hospitals, and all participating doctors for themselves. We 
obtained ethics approval from the University of Leeds 
School of Medicine Research Ethics Committee 
(MREC15-016) and the Guangxi Institute Review Boards at 
the Guangxi Autonomous Region Centre for Disease 
Control and Prevention (CDC) (GXIRB2014-0036), and 
have previously published the trial protocol.12
Participants
In China, all residents living in rural areas are enrolled 
into the rural health insurance scheme, which requires a 
prescription for each clinical consultation to record the 
workload of a health facility or doctor for reimbursement 
purposes. In theory, a prescription might contain medi-
cations or might not, but in practice most prescriptions 
have one or more medications, especially as patients often 
feel untreated if no medication is given.4,14
Participants were eligible if they attended a township 
hospital as an outpatient, were aged between 2 and 14 years 
old, and were given a prescription following a primary 
diagnosis of a upper respiratory tract infection, as defined 
according to the International Classification of Diseases 
10th Revision.15 Only anonymous patient prescription data 
were used. Therefore, our ethics committees granted that 
individual patient consent was not required in the trial. 
Since we have masked patient identities, we did not have 
the capacity to follow up those who developed bacterial 
infections as a consequence of not being given antibiotics. 
Therefore, we excluded children younger than 2 years of 
age for safety reasons because they might be more 
vulnerable to secondary bacterial infections. We also 
excluded any children who had a secondary diagnosis of 
lower respiratory tract infections, such as pneumonia, in 
whom antibiotics would be appropriate, or children who 
had any severe or chronic disease requiring long-term 
antibiotic treatment or prophylaxis.
Randomisation and masking
The trial statistician (JPH) randomly assigned all 
25 eligible township hospitals, stratified by county, to 
either the intervention or control, using a computer 
programme written in R (version 3.2.2). In Rong county, 
hospitals were allocated in a 1:1 ratio of intervention to 
control, whereas in Liujiang county hospitals were 
allocated in a 5:6 ratio (selected to reduce our workload 
on interventions). Three township hospitals from the 
intervention and three from the control group in Rong 
county were then immediately selected for the internal 
pilot trial by simple randomisation using the computer 
program. Patients were masked to the intervention 
assigned to them in the trial. Because of the design of 
the intervention, it was not possible to mask doctors to 
the intervention, but we used the PROBE design16 to 
ensure that those who extracted or analysed the data 
were masked to group allocation.
Intervention procedures
The intervention aimed to change doctors’ antibiotic-
prescribing behaviour for childhood upper respiratory 
tract infections. We developed clinical guidelines based 
on the latest Chinese and international antibiotic-use 
guidelines that focus on upper respiratory tract infections 
with or without fever)17,18 The guidelines covered best 
practice in clinical assessment, diagnosis, and treatment 
of respiratory diseases or upper respiratory tract infections 
for patients of all ages, using evidence-based criteria such 
as an adapted version of the UK National Institute for 
Health and Care Excellence (NICE) traffic-light system for 
assessing possible sepsis and referral in children with 
fever.18 We provided a 2-h interactive training session 
(integrated within routine training procedures to improve 
replicability) for doctors within the first month following 
the implementation of the intervention. The training 
covered use of the guidelines, as well as communication 
skills and case study-based roleplays to help doctors feel 
confident in correctly diagnosing children with viral 
upper respiratory tract infections and explaining to 
caregivers why antibiotics were not needed for such 
infections. The other key intervention was monthly peer-
review meetings, integrated within routine monthly 
administrative meetings, during which doctors’ antibiotic 
prescribing rates were assessed (see appendix p 3 for full 
details). Finally, we developed leaflets and a video 
educating caregivers about antibiotics. The leaflets were 
provided to parents and caregivers by doctors during 
consultations, and the educational video was played on a 
loop in the hospital waiting areas.
For the guidelines see http://
comdis-hsd.leeds.ac.uk/projects
See Online for appendix
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Control procedures
In hospitals allocated to the control group, doctors 
continued prescribing antibiotics according to existing 
practices. Antibiotics were given at the individual 
clinician’s discretion, and no systematic health education 
messages about antibiotic prescribing were provided to 
patients. Monthly routine administrative meetings were 
held in township hospitals, but without any prescribing 
peer-review component.
Data collection
We collected all available prescriptions issued to eligible 
patients in hospitals in both groups during the 3 months 
prior to the implementation of the intervention (baseline), 
and during the final 3 months of the 6-month intervention 
period (endline). We did not use all available prescriptions 
because of ethical concerns about identifying township 
hospitals from their relative prescribing levels. In Rong 
county, we extracted all electronic health records, whereas 
in Liujiang county we photocopied all paper prescriptions 
and inputted them electronically. We excluded any 
patient-identifiable information (eg, name, address, and 
ID number) before data extraction. Based on our sample 
size, we then selected 200 of these prescriptions (or all of 
them if <200 existed) from each township hospital at 
baseline and at endline, via simple random selection 
using a computer program. We extracted patients’ 
character istics, diagnoses, medications, and costs from 
prescriptions, and linked prescribing doctors’ 
character istics from their employment records.
Outcomes
All outcomes were calculated at the cluster level, either as 
proportions or means, based on eligible endline 
prescriptions. The primary outcome was the antibiotic 
prescription rate, defined as the proportion of prescriptions 
for upper respiratory tract infections that include at least 
one antibiotic. Most upper respiratory tract infections do 
not require antibiotics, and the antibiotic prescription rate 
is therefore a common proxy measure of inappropriate 
prescribing (which was too resource-intensive to measure 
directly).19 To explore whether or not the intervention 
affected relative rates of prescribing among different types 
of antibiotic, we used three secondary outcomes. These 
secondary outcomes were the proportion of antibiotic-
containing prescriptions including two or more antibiotics 
(the multiple antibiotic prescription rate); the proportion 
of antibiotic-containing prescriptions including at least 
one broad-spectrum antibiotic (the broad-spectrum 
antibiotic prescription rate); and the proportion of 
antibiotic-containing prescriptions including at least one 
intravenous antibiotic (the intravenous antibiotic pre-
scription rate). Co-amoxiclav, second-generation and 
third-generation cephalosporins, and azithromycin are 
regarded as broad-spectrum for upper respiratory tract 
infections.17,18 To explore any changes in the prescribing 
rates of other medications, we used five additional 
secondary outcomes: the proportion of prescriptions 
containing either antivirals, glucocorticoids, vitamins, 
traditional Chinese medicines, or any other non-antibiotic 
medicine(s). Finally, to assess whether or not the 
intervention affected medical costs for patients, we used 
three further secondary outcomes: the full prescription 
cost (including the total of any consultation costs, 
treatments costs, and medications costs); the antibiotic 
medication cost; and the non-antibiotic medication cost. 
Costs are presented in US dollars (US$), converted from 
the Chinese currency Renminbi (RMB). We added several 
of these outcomes as exploratory outcomes post-protocol: 
the intravenous antibiotic prescription rate, the 
prescription rate for all non-antibiotic medications, the 
antibiotics medication cost, and the non-antibiotics 
medication cost. A protocol-planned secondary outcome 
of the quinolone prescription rate was not analysed 
because these prescriptions were very rare.
Statistical analysis
Based on our exploratory work10 we estimated that the 
antibiotic prescribing rate for children with upper 
respiratory tract infections would be 50%, and that we 
could collect and process an average of 200 prescriptions 
per township hospital (using the harmonic mean due to 
unequal cluster size).20 Based on our systematic review7 
we estimated that the intervention would lead to a 
25% relative reduction in the antibiotic prescribing rate. 
Under the assumption of a coefficient of variation of 
0·15, 10% loss of data from illegible prescriptions, and 
allowing for stratification, we required 24 clusters to 
detect a decrease of this magnitude or greater with 
90% power, using two-sided testing at the 5% significance 
level, and so we included all 25 eligible clusters within 
the two counties.20
We pooled both internal pilot and main trial data for 
analysis, and controlled for seasonality by comparing the 
endline antibiotic prescription rate between the 
intervention and control group during the same period. 
No interim analysis was done. We analysed cluster-level 
summary endline outcomes using methods appropriate 
for stratified, cluster-randomised trials with relatively few 
clusters per group, accounting for between-cluster 
variation.12,20 We estimated the crude absolute effect of 
the intervention on the antibiotic prescription rate by 
estimating the risk difference for the endline antibiotic 
prescription rate, based on a weighted average of stratum-
specific cluster-level endline risk differences, with 
weights inversely proportional to stratum-specific 
variances. We calculated the 95% CIs for this risk 
difference, and did a formal hypothesis test (two-sided 
and at the 5% level), via a stratified t-test. To adjust for 
covariates, we fitted a logistic regression to the individual-
level primary outcome endline data, controlling for 
covariates of interest except the treatment effect. We then 
calculated covariate-adjusted cluster-level difference 
residuals from the model-predicted and observed values, 
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and analysed these using the same method as described 
above. We analysed secondary proportion outcomes 
using the same methods, and also present crude and 
adjusted risk ratio results for all antibiotic prescription 
rate outcomes. We used the same methods to analyse the 
quantitative cost outcomes, but with cluster-level means 
in place of proportions for the crude analysis, and with 
normal linear regression used instead of logistic 
regression to calculate covariate-adjusted difference 
residuals (resulting in crude or adjusted mean 
differences). We also did a range of exploratory (not 
protocol-planned) subgroup analyses on the primary 
outcome based on patient-level and doctor-level 
characteristics (see appendix p 3 for methods). We did 
not adjust the type 1 error rate for our secondary outcome 
and subgroup analyses, but treated them as helping us to 
interpret our primary outcome results.21
Adjusted results controlled for stratum (county); 
cluster-level summary outcome at baseline; patient’s sex, 
age, and payment type (insured or fully out-of-pocket); 
and doctor’s sex, age, and qualification level (≥3 years or 
≥5 years). Crude analyses were done on an intention-to-
treat basis, whereas adjusted and subgroup analyses 
were on a modified intention-to-treat basis due to the use 
of complete cases for which covariate data were missing. 
We used R version 3.3.2 for all statistical analyses.
This study is registered with the ISRCTN registry, 
number ISRCTN14340536.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. XW and ML had access to the raw 
data. The corresponding authors had full access to all the 
data and had final responsibility for the decision to 
submit for publication.
Results
We recruited all 25 eligible township hospitals in the two 
counties, and randomly allocated 12 to the intervention 
group and 13 to the control group. We then implemented 
the intervention in the three internal pilot clusters 
between July 1, 2015, and Dec 31, 2015, and in the 
remaining nine intervention clusters between Oct 1, 2015, 
and March 31, 2016. We obtained and screened 
143 299 baseline and 149 408  endline prescriptions from 
the intervention group, of which 16 467 (11·5%) baseline 
prescriptions and 14 210 (9·5%) endline prescriptions 
were eligible after excluding those based on age and 
diagnoses. In the control group, we extracted and 
screened 94 520 baseline and 101 657 endline prescriptions, 
of which 8527 (9·0%) baseline prescriptions and 
7234 (7·1%) endline prescriptions were eligible. We then 
randomly selected 2349 baseline and 2351 endline 
prescriptions from the intervention group and 
2548 baseline and 2552 endline prescriptions from the 
control group (figure, table 1). We checked pneumonia 
diagnostic codes to see whether doctors might have 
changed diagnosis codes in response to adjusting their 
antibiotic prescribing rates, but we noted no clear changes 
in either upper respiratory tract infection or pneumonia 
diagnostic codes used between baseline and endline in 
either group. There were 956 (0·7%) pneumonia cases at 
baseline and 964 (0·7%) at endline in the intervention 
group, and 569 (0·6%) and 552 (0·5%) in the control 
group, respectively. Overall, baseline and endline patient 
and doctor characteristics were well balanced between 
groups, with some modest (>5%) imbalances in diagnosis 
(acute tonsillitis), payment method, doctor’s sex and 
doctor’s years of work, and a larger (>10%) imbalance in 
doctor’s qualification level (table 1).
Between study baseline and endline, the antibiotic 
prescription rate decreased from 82% to 40% in the 
27 eligible clusters recruited and randomly assigned
13 clusters allocated to and received control
94 520 prescriptions screened for eligibility at 
baseline†
85 993 prescriptions excluded
74 846 ineligible age
10 315 no URTI diagnosed




25 eligible clusters recruited and randomly assigned
101 657 prescriptions screened for eligibility at 
endline†
94 423 prescriptions excluded
80 956 ineligible age
12 303 no URTI diagnosed
1164 secondary diagnosis 
including pneumonia or 
severe disease
2548 baseline (out of 8527) and 2552 endline 
(out of 7234) prescriptions randomly 
selected for analyses
12 clusters allocated to and received 
intervention
143 299 prescriptions screened for eligibility at 
baseline†
126 832 prescriptions excluded
111 387 ineligible age
14 431 no URTI diagnosed
1014 secondary diagnosis 
including pneumonia or
severe disease
149 408 prescriptions screened for eligibility at 
endline†
135 198 prescriptions excluded
118 352 ineligible age
15 630 no URTI diagnosed
1216 secondary diagnosis 
including pneumonia or 
severe disease
2349 baseline (out of 16 467) and 2351 
endline (out of 14 210) prescriptions 
randomly selected for analyses
Figure: Trial profile
URTI=upper respiratory tract infection. Clusters=township hospitals. *We excluded the two township hospitals 
located in the two county centres, because they are not closely comparable to the other hospitals—they have much 
better staff capacity and equipment than their peers, and are located close to the county general hospital. 
†Baseline prescriptions were issued during the 3 months prior to the implementation of the intervention, whereas 
endline prescriptions were issued during the last 3 months of the 6-month intervention period.
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intervention group, and from 75% to 70% in the control 
group. After controlling for potential confounders 
including the baseline antibiotic prescribing rate, 
compared with the control group the decrease in the 
intervention group represented an absolute risk reduction 
in the antibiotic prescribing rate of 29% (95% CI –42 to –16; 
p=0·0002), with no substantial difference in the crude 
results (table 2; see appendix p 9 for risk ratio results). 
Between baseline and endline, the antibiotic prescribing 
rate decreased continuously in the intervention group, but 
not in the control group (appendix p 4). We also noted a 
range in the variation of the antibiotic prescribing rate 
reductions recorded in intervention clusters between 
baseline and endline (from –11% to –74%; mean difference 
–43% [95% CI –55 to –31; p<0·0001 [paired t-test]; appendix 
p 5), whereas control clusters had a much smaller range 
of variation (from 10% to –25%; mean difference –6% 
[95% CI –12 to 1; p=0·07 [paired t-test]; appendix p 5). 
Exploratory crude and adjusted subgroup analyses of the 
intervention’s effect on the antibiotic prescribing rate 
modified by patients’ sex and payment method, and by 
prescribing doctors’ age, sex, and qualification level, all 
showed no significant effects (appendix pp 6–8).
After adjustment, we found no significant effect of 
the intervention on the multiple antibiotic prescribing 
rate, broad-spectrum antibiotic prescribing rate, or 
intravenous antibiotic prescribing rate, with no difference 
in the crude results (table 2; see appendix p 9 for risk ratio 
results). We also found no significant adjusted effect of the 
intervention on the full prescription cost or the non-
antibiotic medication cost (table 3), with no difference in 
the crude results. After adjustment, the mean antibiotic 
cost was significantly lower in the intervention group than 
in the control group, although the crude results showed no 
significant difference (table 3). In our post-hoc analyses, 
we also found no crude or adjusted significant effect of the 
intervention on prescribing rates of glucocorticoids, 
vitamins, or other non-antibiotic medicines (table 4). There 
was a modest, significant increase in the crude antiviral 
prescribing rate in the intervention group compared with 
the control group, but no significant difference in the 
adjusted results, suggesting that the crude difference could 
be explained by confounding (table 4). We also found a 
small but significant increase in the prescribing rate of 
traditional Chinese medicine in both the adjusted and 
crude results (table 4).
Discussion
Our trial is one of the first rigorously designed trials on 
antimicrobial stewardship strategies in LMICs. The 
results show that the intervention package was highly 
effective, with a 29% absolute reduction in the prescribing 
of antibiotics for childhood upper respiratory tract 
infections in primary care facilities in rural China. Our 
study provides a promising programme of antimicrobial 
stewardship strategies for LMICs, with the largest effect 
size ever achieved, compared with the 5–25% absolute 
reduction of antibiotic prescription rate reported in other 
similar trials.19,22 One possible reason for our success is 
that it targeted both providers and caregivers, which 
is more effective than targeting either group alone.7 Part 
of the explanation for why such a large effect was possible 
is that the baseline antibiotic prescription rate was high 
Intervention group (n=12 clusters) Control group (n=13 clusters)
Baseline Endline Baseline Endline
Patients’ characteristics
Prescriptions 2349 2351 2548 2552
Sex
Male 1331 (57%) 1281 (55%) 1363 (54%) 1420 (56%)
Female 1011 (43%) 1058 (45%) 1086 (43%) 1112 (44%)
Missing 7 (<1%) 12 (<1%) 99 (4%) 20 (1%)
Age group, years
2–4 1207 (51%) 1143 (49%) 1313 (52%) 1294 (51%)
5–14 1142 (49%) 1208 (51%) 1235 (49%) 1258 (49%)
Diagnoses
Acute nasopharyngitis 53 (2%) 83 (4%) 68 (3%) 87 (3%)
Acute sinusitis 19 (1%) 11 (1%) 18 (1%) 18 (1%)
Acute pharyngitis 921 (39%) 861 (37%) 1013 (40%) 936 (37%)
Acute tonsillitis 496 (21%) 480 (20%) 583 (23%) 667 (26%)
Acute laryngitis 58 (3%) 1 (<1%) 0 3 (<1%)
Acute upper respiratory 
infections of multiple and 
unspecified sites
802 (34%) 915 (39%) 866 (34%) 841 (33%)
Payment method
Insurance co-payment 1774 (76%) 1544 (66%) 1674 (66%) 1495 (59%)
Fully out-of-pocket 575 (25%) 807 (34%) 874 (34%) 1057 (41%)
Medicines prescribed per patient 4·7 (1·7) 4·0 (1·5) 4·5 (1·7) 3·9 (1·6)
Doctors’ characteristics
Doctors 127 137 160 147
Sex
Male 91 (72%) 102 (75%) 113 (71%) 105 (71%)
Female 33 (26%) 31 (23%) 44 (28%) 41 (28%)
Missing 3 (2%) 4 (3%) 3 (2%) 1 (1%)
Age group (years)
≤35 56 (44%) 60 (44%) 73 (46%) 65 (44%)
36-44 53 (42%) 55 (40%) 59 (37%) 60 (41%)
≥45 15 (12%) 18 (13%) 25 (16%) 21 (14%)
Missing 3 (2%) 4 (3%) 3 (2%) 1 (1%)
Qualification level
3 years’ medical education 101 (80%) 105 (77%) 138 (86%) 129 (88%)
MBBS (5 years’ medical 
education)
23 (18%) 28 (20%) 19 (12%) 17 (12%)
Missing 3 (2%) 4 (3%) 3 (2%) 1 (1%)
Years of work
≤5 18 (14%) 24 (18%) 41 (26%) 40 (27%)
6–10 37 (29%) 38 (28%) 39 (24%) 34 (23%)
≥11 69 (54%) 71 (52%) 77 (48%) 72 (49%)
Missing 3 (2%) 4 (3%) 3 (2%) 1 (1%)
Data are n, n (%), or mean (SD).
Table 1: Baseline and endline patient and doctor characteristics
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in our setting (79% across groups) compared with that in 
high-income countries (typically 20–40%).6,7 However, 
antibiotic prescription rates are typically much higher in 
China and other LMICs than in high-income settings,23 so 
the need for antimicrobial stewardship is more urgent in 
these areas. Almost all previous trials that have attempted 
to reduce antibiotic overuse have been done in high-
income countries, except for two inadequately designed 
and reported studies,11,24 and a recent trial in Vietnam 
showing the effect of using C-reactive protein testing in 
reducing antibiotic use25 (although the relatively high cost 
of C-reactive protein is prohibitive in LMICs).
Intervention group (n=12 
clusters)
Control group (n=13 clusters) Crude risk 
difference at 
endline (95% CI)*




Individual Cluster Individual Cluster
Antibiotic prescription rate‡
Baseline 1936/2349 (82%) 82% (8%) 1922/2548 (75%) 75% (10%) ·· ·· ·· ··
Endline 943/2351 (40%) 40% (19%) 1782/2552 (70%) 70% (14%) –30% (–43 to –17) <0·0001 –29% (–42 to –16) 0·0002
Multiple antibiotic prescription rate§
Baseline 275/1936 (14%) 14% (9%) 255/1922 (13%) 13% (9%) ·· ·· ·· ··
Endline 87/943 (9%) 8% (5%) 117/1782 (7%) 7% (3%) 2% (–1 to 5) 0·14 1% (–2 to 3) 0·57
Broad-spectrum antibiotic prescription rate§
Baseline 1366/1936 (71%) 70% (19%) 1156/1922 (60%) 59% (25%) ·· ·· ·· ··
Endline 545/943 (58%) 60% (22%) 1025/1782 (58%) 54% (25%) 5% (–10 to 20) 0·52 –4% (–11 to 4) 0·3
Intravenous antibiotic prescription rate§
Baseline 802/1936 (41%) 42% (30%) 863/1922 (45%) 45% (28%) ·· ·· ·· ··
Endline 386/943 (41%) 36% (26%) 785/1782 (44%) 45% (22%) –8% (–20 to 5) 0·23 –8% (–16 to 1) 0·07
Individual-level summary data are n/N (%). Cluster-level summary data are mean (SD) of cluster-level outcome percentages. *Crude intervention vs control risk difference 
results account for the stratified, cluster-randomised study design; for the crude analyses all selected prescriptions were included as appropriate. †Adjusted intervention vs 
control risk difference results also account for the effect of patient covariates (sex, age, and payment method), prescribing doctor covariates (sex, age, and qualification level), 
cluster-level outcome at baseline, and stratum (county); for the adjusted overall antibiotic prescription rate analysis, 36 intervention and 67 control prescriptions were 
excluded because of missing covariate data, and for the adjusted analyses of antibiotic category-specific antibiotic prescription rate outcomes, 24 intervention and 27 control 
prescriptions were excluded because of missing covariate data. ‡The unadjusted between-cluster coefficient of variation (k) for the antibiotic prescription rate was 
0·397 overall, 0·466 for the intervention group, and 0·199 for the control group; the intracluster correlation coefficient for the antibiotic prescription rate was 0·198 overall, 
0·146 for the intervention group, and 0·092 for the control group.20 §Antibiotic category-specific antibiotic prescription rate outcomes are based on antibiotic-containing 
prescriptions only.
Table 2: Effect of intervention on antibiotic prescribing
Intervention (n=12 clusters) Control (n=13 clusters) Crude mean 
difference at endline 
(95% CI)*




Individual Cluster Individual Cluster
Full prescription cost (US$)‡
Baseline 5·5 (3·9) 5·5 (1·8) 5·4 (3·1) 5·4 (1·4) ·· ·· ·· ··
Endline 4·9 (3·2) 4·9 (1·2) 5·0 (2·8) 5·0 (1·0) –0·06 (–0·73 to 0·6) 0·84 –0·22 (–0·84 to 0·4) 0·46
Antibiotics cost (US$)§
Baseline 0·6 (0·4) 0.7 (0·04) 0·5 (0·4) 0·7 (0·07) ·· ·· ·· ··
Endline 0·3 (0·4) 0·7 (0·05) 0·5 (0·4) 0·7 (0·06) 0·01 (–0·03 to 0·05) 0·54 –0·2 (–0·29 to –0·11) 0·0004
Other medication cost (US$)¶
Baseline 3·5 (3·8) 2·7 (1·0) 3·4 (2·9) 2·8 (·8) ·· ·· ·· ··
Endline 3·2 (3·0) 3·1 (0·9) 3·1 (2·7) 2·9 (0·8) 0·22 (–0·36 to 0·81) 0·44 0 (–0·59 to 0·58) 1·0
Individual-level summary data are mean (SD). Cluster-level summary data are mean (SD) of cluster-level outcome means. *Crude intervention vs control mean difference 
results account for the stratified, cluster-randomised design, and for the crude analyses all selected prescriptions were included. †Adjusted intervention vs control mean 
difference results also account for the effect of patient covariates (sex, age, and payment method) and prescribing doctor covariates (sex, age, and qualification level), 
cluster-level outcome at baseline, and stratum (county); for all adjusted analyses, 36 intervention and 67 control prescriptions were excluded because of missing covariate 
data. ‡Full prescription cost includes all prescription costs plus any consultation, treatment, and medication costs. §The antibiotics cost includes costs for any antibiotic 
medications only. ¶The other medication cost includes costs for any non-antibiotic medications only. US$ values are based on the currency exchange rate on July 15, 2016, in 
which 1US$=6·68RMB.
Table 3: Effect of intervention on prescription costs
Articles
e1265 www.thelancet.com/lancetgh   Vol 5  December 2017
In the intervention group, we noted a modest reduction 
in antibiotic costs, potentially due to the intervention, but 
no changes in full prescription costs, which is probably 
because antibiotics only account for a small proportion of 
the full prescription costs (around 6–11%). We also 
observed a minor increase in prescribing of traditional 
Chinese medicine in the intervention group, potentially 
due to the intervention influencing doctors to substitute 
traditional Chinese medicines for antibiotics to reassure 
patients, or as a compensation for hospital revenues lost 
due to reduced antibiotic prescribing. These revenues 
can be recouped through traditional Chinese medicine 
prescription because these medicines are exempt from 
the zero mark-up policy introduced in 2009, so hospitals 
still charge a 15% or greater mark-up on them. Another 
area requiring attention is the generally inappropriately 
high prescription rates for antivirals (30–50%) and 
glucocorticoids (20%), which is consistent with other 
findings in China.14 More studies are needed to 
understand this problem, and to develop additional 
interventions to tackle over-prescribing of antivirals and 
glucocorticoids for upper respiratory tract infections. We 
observed a large variation in antibiotic prescription rate 
changes between baseline and endline across the 
intervention clusters, which may be indicative of different 
levels of stewardship in the peer-review meetings. This 
will be reported in our future process evaluation  in a 
separate paper. Nevertheless, even in the intervention 
group, at endline the antibiotic prescription rate was still 
high (40%) compared with high-income countries, which 
means our intervention might need to be more intensive, 
be implemented for longer, or both.
Apart from its effectiveness, the key strength of the trial 
is that it was designed for routine care in a rural low-
resource setting via an embedded process.26 Since 2009, 
China has enacted national health policy reforms to 
regulate antibiotic prescribing. These included the 
creation of an essential medicines list, a central medicine 
procurement system, and a zero mark-up charges policy 
to unlink profits from prescribing in primary care 
facilities, plus a 20% limit for antibiotic prescribing across 
all consultations in all health care facilities.27 Studies have 
shown that these approaches possibly have effects on 
reducing medical expenses, but not on antibiotic 
prescribing.28 Our recent study showed that, at the county 
hospital level, the policy might be associated with reducing 
inappropriate antibiotic prescribing in outpatients, if 
accompanied by an antimicrobial steward ship programme 
that includes guideline training, peer-reviews, and 
restricting non-compliant doctors.29 How ever, purely 
managerial measures, such as posting individual doctors’ 
antibiotic prescription rates publicly, has not been proven 
successful.11 Based on these policies, we developed 
antimicrobial stewardship strategies that fit into the 
routine activities of township hospitals. Our intervention 
can be used in settings with or without electronic 
health records.
Our study has several limitations. First, we were not 
able to measure return visit rates of patients, and so could 
not assess whether or not our intervention increased the 
Intervention (n=12 clusters) Control (n=13 clusters) Crude risk 
difference 
(95% CI)*




Individual Cluster Individual Cluster
Antiviral prescription rate
Baseline 1175/2349 (50%) 50% (24%) 740/2548 (29%) 29% (24%) ·· ·· ·· ··
Endline 1231/2351 (52%) 53% (25%) 860/2552 (34%) 33% (26%) 18% (5 to 30) 0·009 4% (–5 to 14) 0·34
Glucocorticoid prescription rate
Baseline 611/2349 (26%) 26% (19%) 580/2548 (23%) 23% (17%) ·· ·· ·· ··
Endline 455/2351 (19%) 19% (12%) 420/2552 (17%) 17% (13%) 3% (–8 to 13) 0·61 2% (–5 to 10) 0·57
Vitamin prescription rate
Baseline 319/2349 (14%) 14% (7%) 335/2548 (13%) 13% (9%) ·· ·· ·· ··
Endline 205/2351 (9%) 9% (5%) 287/2552 (11%) 11% (7%) –3% (–7 to 1) 0·13 –3% (–6 to 1) 0·12
Traditional Chinese medicine prescription rate
Baseline 1739/2349 (74%) 74% (14%) 1760/2548 (69%) 69% (16%) ·· ·· ·· ··
Endline 1848/2351 (79%) 79% (14%) 1804/2552 (71%) 71% (12%) 7% (2 to 13) 0·015 7% (2 to 11) 0·004
Other non-antibiotic medicine prescription rate
Baseline 1961/2349 (84%) 83% (9%) 2135/2548 (84%) 84% (11%) ·· ·· ·· ··
Endline 1920/2351 (82%) 82% (8%) 2077/2552 (81%) 81% (10%) 0% (–6 to 6) 0·94 0% (–4 to 5) 0·87
Individual-level summary data are n/N (%). Cluster-level summary data are mean (SD) of cluster-level percentages. *Crude intervention vs control risk difference results 
account for the stratified, cluster-randomised design; for the crude analyses, all selected prescriptions were included. †Adjusted intervention vs control risk difference results 
also account for the effect of patient covariates (sex, age, and payment method) and prescribing doctor covariates (sex, age, and qualification level), cluster-level outcome at 
baseline, and stratum (county); for the adjusted analyses, 36 intervention and 67 control prescriptions were excluded because of missing covariate data. All the outcomes in 
this table were added post-protocol but pre-analysis.
Table 4: Effect of intervention on prescribing of non-antibiotic medications
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rate of return visits to hospitals due to illnesses related to 
worsening upper respiratory tract infections. However, 
our intervention approaches are unlikely to cause serious 
bacterial infections as shown in other trials done 
elsewhere.19,30 In China, patients often directly visit county 
hospitals when they develop more severe symptoms, and 
we were not able to record these return visits. Second, our 
indicators were based on prescriptions, not outpatient 
visits. In this setting, a prescription is required for each 
consultation by the rural health insurance scheme to 
record the clinical visit for reimbursement purposes. 
Although patients might visit a doctor and not receive a 
prescription, in practice this is rare because patients in 
China do not generally feel taken care of without being 
given medication(s).4 Even if the outpatient visit cost is 
not covered by the health insurance scheme, patients still 
prefer to register their visits because the scheme covers 
much of their user-fee costs.13 Thus, the use of 
prescriptions as an indicator is unlikely to underestimate 
numbers of outpatient visits in this particular setting. 
Third, some contamination between intervention and 
control clusters might have occurred because the 
townships in different groups were sometimes next to 
each other, potentially reducing effect sizes. However, 
rural residents need to visit their own township hospitals 
as per the regulations of their health insurance schemes, 
so the risk of contamination between clusters was low, 
plus our primary outcome effect size was high, suggesting 
that little—if any—contamination occurred. Fourth, the 
short duration of the intervention (6 months) means that 
longer-term studies are needed to understand how 
sustainable its effect is, and we will therefore be reporting 
on our outcomes at 12 months in a future study. Fifth, 
inappropriate use of antibiotics is also a widespread 
problem in adults in LMICs. We designed the trial for 
children because overuse of antibiotics is more 
challenging in this patient population because parents 
often demand antibiotics to enable a potentially more 
rapid recovery. Additionally, we did not include children 
younger than 2 years old, which limits the generalisability 
of trial results to all children. Future studies could include 
patients of all ages. The guidelines regarding appropriate 
antibiotic use are designed for all patients. Similarly, the 
addition of more training on guidelines for use of 
multiple antibiotics, antivirals, and intravenous infusions 
might be necessary. Finally, given our inability to mask 
doctors in the trial, it is possible that the Hawthorne effect 
could account for part of the intervention effect. However, 
to reduce the influence of any such effect we had a 
3-month period during which the intervention was 
implemented but no outcome data were collected in 
either group, to allow doctors to become familiar with the 
intervention processes as part of their routine practices 
before we collected outcome data.
To conclude, our study shows that, in primary care 
facilities in rural China, our intervention, involving a 
doctors’ clinical guide, training, and prescribing peer 
review, plus information for caregivers provided by 
doctors, leaflets, and videos, has substantially reduced 
inappropriate prescribing of antibiotics for childhood 
upper respiratory tract infections. The intervention was 
designed for scale-up through its integration within the 
rural health system in China, and could be adapted to 
other similar settings in LMICs facing the problem of 
antibiotic overuse.
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